Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siMDR-1
- Development stage
- Preclinical
- Lead developer
- Northeastern University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
siMDR-1 is a small interfering RNA (siRNA) designed to target and silence the expression of the *MDR1* (multidrug resistance 1) gene, which encodes the efflux transporter P-glycoprotein (P-gp). Overexpression of P-gp in cancer cells is a primary driver of multidrug resistance (MDR), as it actively pumps chemotherapeutic agents out of the cell. By degrading *MDR1* mRNA via the RNA-induced silencing complex (RISC) pathway, siMDR-1 downregulates P-gp expression, thereby restoring cellular sensitivity to co-administered chemotherapeutics such as doxorubicin. Primarily utilized as a research-use-only reagent, siMDR-1 has been extensively investigated in preclinical academic settings—particularly at Northeastern University—using various nanoparticle delivery systems (including mixed dendrimer micelles and liposomes) to target drug-resistant tumors.
- Other names
- MDR1 siRNAMDR-1 siRNAMDR 1 siRNAsiMDR1siMDR-1siMDR 1
02
Targets
ABCB1 (P-glycoprotein)
Beyond the preview
Go deeper on siMDR-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siMDR-1.